We have shown previously that low‐density lipoprotein (LDL) can be oxidized in the lysosomes of macrophages, that this oxidation can be inhibited by cysteamine, an antioxidant that accumulates in lysosomes, and that this drug decreases atherosclerosis in LDL receptor–deficient mice fed a high‐fat diet. We have now performed a regression study with cysteamine, which is … Continue reading #Cysteamine Decreases Low‐Density Lipoprotein Oxidation, Causes Regression of #Atherosclerosis, and Improves #Liver and Muscle Function in Low‐Density Lipoprotein Receptor–Deficient Mice
Category: Cardiology
The association between body mass index (BMI) and clinical outcomes following an acute myocardial infarction (AMI) remains controversial. Our objective was to investigate the relationship between BMI and AMI presentation, in-hospital clinical course and mortality in the contemporary era of AMI management. Methods: Patients, hospitalized for an AMI between October 2015 and December 2016, were … Continue reading The Relationship Between Body #Mass Index and In-Hospital #Mortality in the Contemporary Era of an Acute Myocardial #Infarction Management
Premature death from all causes and cardiovascular disease (CVD) causes is higher among persons with diabetes. Objective To investigate the association between time spent cycling and all-cause and CVD mortality among persons with diabetes, as well as to evaluate the association between change in time spent cycling and risk of all-cause and CVD mortality. Design, … Continue reading Association of #Cycling With All-Cause and #Cardiovascular Disease Mortality Among Persons With #DiabetesThe European Prospective Investigation Into Cancer and Nutrition (EPIC) Study
Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin–kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing. METHODSWe enrolled patients with atherosclerotic cardiovascular disease (ORION-10 trial) and patients with atherosclerotic cardiovascular disease or an atherosclerotic cardiovascular disease risk equivalent (ORION-11 trial) who had elevated … Continue reading Two Phase 3 Trials of Inclisiran in Patients with Elevated #LDL Cholesterol
